3SBIOINC.

China Mainland
Company Profile
  • Year Established: 1993
  • Total Assets(USD): More than 99,999,999
  • Total Number of Staff: more than 1000
  • Main Competitive Advantages: Brand Name,International Approvals/Standards,Experienced R&D Staff,Production Capacity,Large Product Line,Contract Manufacturing (CRO,CMO),Quality Service
  • Business Type: Trading Company,Manufacturer
  • R&D Capacity: Own Brand
  • Annual Turnover(USD) : More than 99,999,999
  • Main Sales Markets : North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

3SBio Group has always been committed to solving the problem of clinical drug use for patients, constantly conquering the challenges of the disease, using high-quality drugs to improve the quality of life of patients, and working hard for the benefit of human health.  We have five major production bases in the world, located in: Shenyang, Shanghai, Shenzhen, Hangzhou and Italy. We have accumulated a wealth of professional experience and knowledge in the manufacture of biopharmaceuticals. Our products cover various therapeutic fields, such as tumor, autoimmunity, nephrology, metabolism and dermatology and are in the market leading position and have strong growth momentum and huge growth potential: • TPIAO: The world’s only commercial recombinant human thrombopoietin (rhTPO) which is an independent research and development product. • YISAIPU: The first tumor necrosis factor (TNF-α) inhibitor in the field of rheumatism in China, as well as the first fully human antibody drug listed in China. • Cipterbin: It is the first innovative anti-HER2 monoclonal antibody in China with the engineered Fc region, optimized production process and a stronger ADCC effect. • Epiao and Sepo: The leaders of China’s recombinant human erythropoin market. • Enter into an exclusive license agreement with AstraZeneca, obtaining the commercialization rights for Type 2 diabetes drugs Byetta and Bydureon in China. • Enter into the exclusive license agreement with Lilly China, obtaining the commercialization rights for insulin product Humulin® in China.

Year Established: 1993

Total Assets(USD): More than 99,999,999

Total Number of Staff: more than 1000

Main Competitive Advantages: Brand Name,International Approvals/Standards,Experienced R&D Staff,Production Capacity,Large Product Line,Contract Manufacturing (CRO,CMO),Quality Service

Business Type: Trading Company,Manufacturer

R&D Capacity: Own Brand

Annual Turnover(USD) : More than 99,999,999

Main Sales Markets : North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Top Products
Copyright 2006-2022 Shanghai Sinoexpo Informa Markets International Exhibition Co. Ltd (All Rights Reserved) 沪ICP备05034851号-182
Powered by
×